Louisiana State Employees Retirement System Cuts Stake in Boston Scientific Corporation $BSX

Louisiana State Employees Retirement System reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 1.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 78,100 shares of the medical equipment provider’s stock after selling 1,200 shares during the period. Louisiana State Employees Retirement System’s holdings in Boston Scientific were worth $8,389,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. 1248 Management LLC purchased a new position in Boston Scientific during the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the first quarter valued at $27,000. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific during the second quarter valued at $37,000. Finally, Activest Wealth Management raised its stake in Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

BSX stock opened at $95.86 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The business has a 50-day moving average price of $102.53 and a 200 day moving average price of $101.99. The company has a market capitalization of $142.05 billion, a P/E ratio of 57.06, a PEG ratio of 2.33 and a beta of 0.61. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $17,972,457 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of a number of research reports. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Raymond James Financial lifted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Canaccord Genuity Group increased their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $120.71.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.